Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor monotherapy after 3 months versus 12 months of dual antiplatelet therapy in diabetic patients with acute coronary syndrome undergoing PCI
PACTR202511832264697Completed
- Sponsor
- Ain Shams University
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of ticagrelor in acute coronary syndrome (ACS) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Ain Shams University. Primary endpoint: Major adverse cardiovascular events (MACE). Started Nov 2022; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on PACTR202511832264697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202511832264697.